{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"1830","value":"930"},{"groupId":"OG001","lowerLimit":"0.994","upperLimit":"1480","value":"41.9"},{"groupId":"OG002","lowerLimit":"17.1","upperLimit":"1830","value":"1040"},{"groupId":"OG003","lowerLimit":"26.8","upperLimit":"126","value":"59.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"Tlast is the time of last observed quantifiable concentration in peripheral blood. Tlast, based on the transgene level data by qPCR, was summarized by Month 3 response, per Independent Review Committee assessment. This time frame reflects maximum duration of 60 months up to which the transgene levels were collected.","dispersionType":"Full Range","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG001","title":"Tisagenlecleucel - Main Cohort: SD/PD/UNK"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - Cohort A: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG003","title":"Tisagenlecleucel - Cohort A: SD/PD/UNK"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel with valid PK assessments.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (Pk): Tlast","type":"SECONDARY","unitOfMeasure":"days"}